Naval Daver, M.D.
@Daver_Leukemia
Interests: #AML , #MDS, #Immunotherapy, #FLT3, #TP53 . Faculty at @LeukemiaMDA. Clinical research, education. Dad of three. Tweets are mine.
ID:2920960866
http://faculty.mdanderson.org/Naval_Daver/Default.asp?SNID=0 06-12-2014 20:53:58
1,3K Tweets
4,9K Followers
4,2K Following
Follow People
Amer Zeidan MBBS,MHS عامر زيدان
#Leukemia doctor focusing on #MDSsm & #AMLsm. Personal/own opinions. COI https://t.co/6XkF8CmtrK
Nico Gagelmann
@TheEBMT_Trainee co-chair. Hematology. Medicine. Science. Train. Think. Implement an integral actuality.
Naveen Pemmaraju, MD
Professor, Leukemia; Executive Director-Cancer Medicine for MDACC Cancer Network | Director #BPDCN Program | #MPNSM #leusm #TeamPemm | Tweets:my own opinions
Vincent Rajkumar
Editor-in-Chief, Blood Cancer Journal; Oncologist; Cancer Research; Opinions are solely my personal views https://t.co/HOGYJSpsoG
Sanam Loghavi, MD صنم لغوی 🔬🧬
Hematopathologist/Molecular Pathologist/Director of ECOG-ACRIN Leukemia Bank @mdandersonnews - Editor in Chief #ASHImageBank - #hemepath #molpath #IMG
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease Wei Ying Jen @drhkantarjian @tapkadia @nicholasshortmd @musayilmazmd @gborthakur @daver_leukemia
buff.ly/4axvd56
MRD at the end of induction may be 1 of the few prognostic variables for event-free survival in pediatric T-cell lymphoblastic lymphoma.
ow.ly/2YCc50RJs2t #lymphoidneoplasia #clinicaltrialsandobservations #CMEarticle
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study AmericanJournalofHematology
onlinelibrary.wiley.com/doi/full/10.10…
Sure excited about this meeting. We have an amazing list of speakers. Stay tuned!
Krish Patel Fred Hutchinson Cancer Center #CART
Dr. Naval Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia MD Anderson Cancer Center. He's a rockstar in #leukemia research! Go give him a follow Naval Daver, M.D.. #FollowFriday
Join us for our Post-ASCO & EHA 2024 Highlights 📣 🩸
Featuring presentations & panel discussions on selected abstracts from #ASCO & #EHA 2024 🔦
REGISTER 👉 vjhemonc.com/feature/post-a…
#EHA 2024 #ASCO 24 Claire Harrison Shaji Kumar Naval Daver, M.D. Anna Sureda Matthew Davids, MD, MMSc Amer Zeidan MBBS,MHS عامر زيدان
Welcome to NYC Naval Daver, M.D. ! Looking forward to your visit to Montefiore Health System Albert Einstein College of Medicine - Official tomorrow!! Jean George's JoJo on the UES hit the spot tonight! 😋Marina Konopleva EinsteinSCI
Congratulations to the 2024 MD Anderson-UTH Grad GSBS graduating class for this remarkable milestone. Thank you for the outstanding contributions you have made to science throughout your MD Anderson Cancer Center training and will continue to make through your careers. #EndCancer
Learn to formulate personalized #AML treatment plans that leverage team-based practice principles as upfront therapy, in maintenance settings, and for R/R disease. HealthTree Foundation for AML bit.ly/2024AMLT #ASCO24 #HemOnc #PeerView Naval Daver, M.D. Eunice Wang MD
It’s MDS and HSCT week!!!🤩 off the press in Blood Journal 👉Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms? ashpublications.org/blood/article-…
Today we celebrate Emily Whitehead Foundation 12 years cancer free 👏, and give our thanks to all patients who have contributed to #CARTCell #immunotherapy development.
For those trying to decide between traditional Medicare and Medicare Advantage — please read this article. Mayo Clinic Proceedings
Hagop Kantarjian,MD Amer Zeidan MBBS,MHS عامر زيدان #MedTwitter
cc: Andy Slavitt 🇺🇦 Deb Whitman
Link:
mayoclinicproceedings.org/pb-assets/Heal…
Honored to be co-senior author on this effort led by Dr Della Porta combining GenoMed and Moffitt database. Moffitt Cancer Center Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of AHSCT in Pts With MDS | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
“There’s much more optimism and hope that we will be able to prolong life and improve or maintain a good quality of life in relapsed AML,” says our Naval Daver, M.D..
Here, he shares updates on novel emerging therapies: brnw.ch/21wJFLo OncLive.com #leukemia #EndCancer
Join us for our Post-ASCO & EHA 2024 Highlights 📣 🩸
Featuring presentations & panel discussions on selected abstracts from #ASCO & #EHA 2024 🔦
REGISTER 👉 vjhemonc.com/feature/post-a…
#EHA 2024 #ASCO 24 Claire Harrison Shaji Kumar Naval Daver, M.D. Anna Sureda Matthew Davids, MD, MMSc Amer Zeidan MBBS,MHS عامر زيدان
